Protection of Endothelial Cells by Dextran Sulfate in Rats with Thrombotic Microangiopathy
Open Access
- 1 October 2005
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 16 (10), 2997-3005
- https://doi.org/10.1681/asn.2005020137
Abstract
The characteristic features of thrombotic microangiopathy (TMA) include glomerular and peritubular capillary endothelial cell injury in association with loss of heparan sulfate proteoglycans on the cell surface and thrombus formation, followed by subsequent ischemic tubulointerstitial damage. It therefore was hypothesized that dextran sulfate (DXS) may protect the kidney against endothelial damage in a model of TMA. TMA was induced in rats by renal artery perfusion of an antiglomerular endothelial antibody, followed by the administration of DXS or vehicle. Renal damage was assessed by histologic analysis and measurements of blood urea nitrogen and creatinine. Whereas control rats developed severe renal failure with extensive glomerular and tubular injury, administration of DXS significantly protected renal function and preserved the glomerular endothelium and peritubular capillaries. The beneficial effect of DXS could be attributed to the ability of DXS to protect endothelial cells from coagulation and complement activation, as demonstrated by the histologic analysis. In addition, binding of the administered DXS to the surface of the glomerular endothelium was confirmed in TMA rats, suggesting that DXS acts as a “repair coat” of injured glomerular endothelium. In conclusion, DXS protects the kidney from experimental TMA. This protection may be mediated by DXS’s binding directly to the surface of glomerular endothelium and amelioration of coagulation, complement activation, and cellular matrix loss.Keywords
This publication has 28 references indexed in Scilit:
- Heparan sulfate proteoglycans in glomerular inflammationKidney International, 2004
- Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cellsTransplantation, 2003
- Syndecans in inflammationThe FASEB Journal, 2003
- Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathyKidney International, 2000
- Glomerular heparan sulfate alterations: Mechanisms and relevance for proteinuriaKidney International, 2000
- The plasma membrane-actin linking protein, ezrin, is a glomerular epithelial cell marker in glomerulogenesis, in the adult kidney and in glomerular injuryKidney International, 1998
- Autoantibodies to Vascular Heparan Sulfate Proteoglycan in Systemic Lupus Erythematosus React with Endothelial Cells and Inhibit the Formation of Thrombin-Antithrombin III ComplexesClinical Immunology and Immunopathology, 1994
- Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection.The Journal of Experimental Medicine, 1990
- Structure-function relationships in the inhibitory effect of heparin on complement activation: Independency of the anti-coagulant and anti-complementary sites on the heparin moleculeMolecular Immunology, 1988
- Hemolytic‐uremic Syndrome: An Analysis of the Natural History and Prognostic FeaturesActa Paediatrica, 1984